SG Americas Securities
HRTX icon

SG Americas Securities’s Heron Therapeutics HRTX Stock Holding History

SG Americas Securities’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,377
Closed -$32K – 3443
2025
Q4 		$32K Buy
24,377
+6,858
+39% +$8.47K ﹤0.01% 3415
2025
Q3 		$22K Sell
17,519
-5,954
-25% -$9.44K ﹤0.01% 3282
2025
Q2 		$49K Sell
23,473
-45,574
-66% -$93.1K ﹤0.01% 2764
2025
Q1 		$152K Sell
69,047
-2,576
-4% -$5K ﹤0.01% 2729
2024
Q4 		$110K Buy
71,623
+706
+1% +$1.14K ﹤0.01% 2669
2024
Q3 		$141K Sell
70,917
-127,269
-64% -$304K ﹤0.01% 2790
2024
Q2 		$694K Buy
+198,186
New +$609K ﹤0.01% 1505
2024
Q1 		– Sell
-26,464
Closed -$45K – 3172
2023
Q4 		$45K Sell
26,464
-4,096
-13% -$4.51K ﹤0.01% 2935
2023
Q3 		$31K Buy
+30,560
New +$43.5K ﹤0.01% 3010
2023
Q2 		– Sell
-100,968
Closed -$152K – 2662
2023
Q1 		$152K Buy
+100,968
New +$253K ﹤0.01% 2634
2022
Q4 		– Sell
-14,127
Closed -$60K – 3189
2022
Q3 		$60K Sell
14,127
-79,139
-85% -$310K ﹤0.01% 2966
2022
Q2 		$260K Buy
+93,266
New +$375K ﹤0.01% 2485
2021
Q4 		– Sell
-41,535
Closed -$444K – 3569
2021
Q3 		$444K Buy
+41,535
New +$506K ﹤0.01% 2617
2021
Q2 		– Sell
-18,001
Closed -$292K – 3015
2021
Q1 		$292K Sell
18,001
-41,897
-70% -$747K ﹤0.01% 2406
2020
Q4 		$1.27M Buy
59,898
+6,195
+12% +$108K 0.01% 1401
2020
Q3 		$796K Buy
53,703
+46,650
+661% +$728K 0.01% 1332
2020
Q2 		$104K Sell
7,053
-48,183
-87% -$792K ﹤0.01% 3345
2020
Q1 		$648K Buy
55,236
+41,459
+301% +$779K 0.01% 1619
2019
Q4 		$324K Buy
13,777
+4,054
+42% +$89.7K ﹤0.01% 2136
2019
Q3 		$180K Buy
+9,723
New +$179K ﹤0.01% 2413
2019
Q2 		– Sell
-6,181
Closed -$151K – 3236
2019
Q1 		$151K Buy
+6,181
New +$162K ﹤0.01% 2773
2018
Q3 		– Sell
-5,458
Closed -$212K – 3285
2018
Q2 		$212K Sell
5,458
-1,164
-18% -$37.1K ﹤0.01% 2571
2018
Q1 		$183K Buy
+6,622
New +$150K ﹤0.01% 2486
2016
Q2 		– Sell
-7,371
Closed -$140K – 2782
2016
Q1 		$140K Buy
+7,371
New +$145K ﹤0.01% 2415
2014
Q3 		– Sell
-20,448
Closed -$252K – 2722
2014
Q2 		$252K Buy
+20,448
New +$244K ﹤0.01% 1922

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

SG Americas Securities's HRTX Position: Q1 2026 in Review

SG Americas Securities sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 24,377 shares — an estimated $32K sold.

SG Americas Securities first reported a position in HRTX in Q2 2014 and held it in 25 quarters. The position peaked at $1.27M in Q4 2020. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • SG Americas Securities reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 24,377 Heron Therapeutics shares in Q1 2026, an estimated $32K.
  • SG Americas Securities first reported a position in Heron Therapeutics in Q2 2014 and held it in 25 quarters.
  • SG Americas Securities's Heron Therapeutics position peaked at $1.27M in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.